Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
February 03 2023 - 11:35AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
February 3, 2023
________________
NOVO NORDISK A/S
(Exact name of
Registrant as specified in its charter)
Novo Alle 1
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under cover
of Form 20-F or Form 40-F
Form 20-F [X] |
Form 40-F [ ] |
Indicate by check mark whether the registrant by furnishing the information contained in this
Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
If “Yes” is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g-32(b):82-________
Trading
in Novo Nordisk shares by board members, executives and associated persons
Bagsværd,
Denmark, 3 February 2023 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares
by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014
on market abuse.
The company’s board members, executives and their
associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s
board members, executives and their associated persons.
Please find below a statement of such trading in shares issued
by Novo Nordisk.
1 |
Details
of the person discharging managerial responsibilities/person closely associated |
a) |
Name of the Board |
Emlika ApS |
|
member/Executive/Associated Person |
(Closely associated to board member Jeppe Christiansen) |
2 |
Reason for the notification |
a) |
Position/status |
Member of the Board of Directors |
b) |
Initial notification/Amendment |
Initial notification |
3 |
Details of the issuer |
a) |
Name |
Novo Nordisk A/S |
b) |
LEI |
549300DAQ1CVT6CXN342 |
4 |
Details of the transaction(s) |
Novo Nordisk A/S
Investor Relations |
Novo Alle 1
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
www.novonordisk.com
CVR no: 24 25 67 90 |
|
|
Company announcement No 7 / 2023 |
a) |
Description of the financial instrument, |
Shares |
|
|
type of instrument, |
|
|
|
|
|
Identification code |
Novo Nordisk B DK0060534915 |
|
b) |
Nature of the transaction |
Purchase |
|
c) |
Price(s) and volume(s) |
|
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
DKK 910.85 |
11,000 shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
d) |
Aggregated information |
|
|
|
|
|
· Aggregated volume |
11,000 Shares |
|
|
· Price |
DKK 910.85 |
|
e) |
Date of the transaction |
2023-02-02 |
|
f) |
Place of the transaction |
Nasdaq Copenhagen (XCSE) |
|
|
Novo
Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat
diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific
breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 54,400
people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B).
Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn and
YouTube.
Contact for further information
Media: |
|
Ambre Brown Morley
+45 3079 9289
abmo@novonordisk.com |
Natalia Salomao Abrahao
(US)
+1 848 304 1027
niaa@novonordisk.com |
|
|
|
|
Investors: |
|
Daniel Muusmann
Bohsen
+45 3075 2175
dabo@novonordisk.com |
Jacob Martin Wiborg
Rode
+45 3075 5956
jrde@novonordisk.com |
Novo Nordisk A/S
Investor Relations |
Novo Alle 1
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
www.novonordisk.com
CVR no: 24 25 67 90 |
|
|
Company announcement No 7 / 2023 |
David Heiberg Landsted
+45 3077 6915
dhel@novonordisk.com |
Mark Joseph Root (US)
+1 848 213 3219
mjhr@novonordisk.com |
Novo Nordisk A/S
Investor Relations |
Novo Alle 1
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
www.novonordisk.com
CVR no: 24 25 67 90 |
|
|
Company announcement No 7 / 2023 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: February 3, 2023 |
NOVO NORDISK A/S
Lars Fruergaard Jørgensen
Chief Executive Officer |
Novo Nordisk (PK) (USOTC:NONOF)
Historical Stock Chart
From Jun 2024 to Jul 2024
Novo Nordisk (PK) (USOTC:NONOF)
Historical Stock Chart
From Jul 2023 to Jul 2024